1Jackson TC, Rani A, Kumar A, Foster TC. Regional hippocampal differences in AKT survival signaling across the lifespan: implica- tions for CA1 vulnerability with aging. Cell Death Differ 2009, 16: 439-448.
2Nie K, Yu JC, Fu Y, Cheng HY, Chen FY, Qu Y, et al. Age-related decrease in constructive activation of Akt/PKB in SAMP10 hip- pocampus. Biochem Biophys Res Commun 2009, 378:103-107.
3Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al. Role oftranslocation in the activation and function of pro- tein kinase B. J Biol Chem 1997, 272: 31515-31524.
4Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17: 313-325.
5Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005, 9: 59-71.
6Pastor MD, Garcia-Yebenes I, Fradejas N, P6rez-Ortiz JM, Mora- Lee S, Tranque P, et al. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J Biol Chem 2009, 284(33): 22067-22078.
7Condorelli F, Salomoni P, Cotteret S, Cesi V, Srinivasula SM, AI- nemri ES, et al. Caspase cleavage enhances the apoptosis-inducing effects of BAD. Mol Cell Biol 2001, 21: 3025-3036.
8Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
9Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, et al. Role of the Akt/FoxO3a pathway in TGF-betal-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 2006, 17: 3325-3335.
3CRAIG-SCHAPIRO R, KUHN M, XIONG C, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer' s disease diagnosis and prognosis[ J]. PLoS One ,2011,6 (4) : e18850.
4SU JH,ANDERSON AJ, CRIBBS DH, et al. Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death [ J ]. Neurobiol Dis, 2003,12 ( 3 ) : 182- 193.
5ERTEN-LYONS D, JACOBSON A, KRAMER P, et al. The FAS gene, brain volume, and disease progression in Alzheimer's disease [ J]. Alzheimers Dement,2010, 6(2) :118-124.
6COLLAZIOL D, LUZ C, DORNELLES F, et al. Psychoneurodendocrine correlates of lymphocyte subsets during healthy ageing [ J ]. Mech Ageing Dev, 2004,125 ( 3 ) :219-227.
7PROUSSAKOVA OV, RABAYA NA, MOSHNIKOVA AB, et al. Oligomerization of soluble Fas antigen indues its eytotoxicity [ J]. J Biol Chem, 2003,278 (38) :36236-36241.
8CHARRILAUT-MARLANGUE C, MARGAIL I, REPRESA A, et al. Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis [J]. J Cereb Blood Flow Metab, 1996, 16(2): 186-194.
9LONGA E Z, WEINSTEIN P R, CARLOTN S, et al. Reversible middle cerebral artery occusion without craniotomy in rats [J]. Stroke, 1989, 20(1): 84-91.
